Syschem India Board to Review FY26 Results and Appoint Auditor

Syschem India's Board of Directors will meet on May 25, 2026, to finalize audited financial results for the fiscal year ended March 31, 2026, and appoint the Internal Auditor for FY2026-27. The company has also closed its trading window for designated persons and their relatives. Investors are watching for formal financial disclosure amid recent operational and legal challenges.

Meeting Agenda

Syschem India Limited announced its Board of Directors will convene on May 25, 2026. The main points for discussion are:

• Approval of audited financial results for the fiscal year that concluded on March 31, 2026.
• Appointment of the Internal Auditor for the financial year 2026-27.

The company also informed of a temporary closure of its trading window for designated persons and their relatives.

Why This Meeting is Important

This board meeting is a standard regulatory step to formally approve the company's financial performance for the past fiscal year. Appointing an internal auditor is key to maintaining strong financial oversight and compliance for the new fiscal year. The trading window closure is a common practice to prevent insider trading ahead of sensitive corporate announcements.

Company Background and Recent Challenges

Syschem India Ltd. is based in Chandigarh, India, and has been manufacturing Active Pharmaceutical Ingredients (APIs), intermediates, bulk drugs, and specialty chemicals since 1993. The company also offers contract manufacturing and custom synthesis services.

Financially, the company reported improved performance in the quarter ended December 2025, with a Net Profit of ₹4 Crore, a significant 729% year-on-year growth, compared to ₹54,000 for FY2025.

However, Syschem India has recently faced significant issues. On April 15, 2026, the company reported a cyber fraud that led to an unauthorized fund transfer of ₹1.96 crore. Additionally, it received a demand notice from qp Pharmachem Limited for ₹10.59 crore under the Insolvency and Bankruptcy Code (IBC).

Risks to Watch

The recent cyber fraud resulting in a ₹1.96 crore loss and the ₹10.59 crore demand notice under the IBC point to recent operational and financial issues the company is navigating. The temporary closure of the trading window restricts insider trading until the official financial results are announced.

Peer Comparison

Syschem India operates in the competitive pharmaceutical sector, focusing on API and bulk drug manufacturing. Its peers include established companies such as Laurus Labs, Hikal, Divi's Laboratories, Aurobindo Pharma, Cipla, and Dr. Reddy's Laboratories.

What to Track Next

Investors will be monitoring the official disclosure of Syschem India's audited financial results for FY2025-26 following the board meeting. Key points to watch include:

• Details of the appointed Internal Auditor for FY2026-27.
• The date when the trading window is set to reopen.
• Any further developments regarding the cyber fraud incident and the IBC demand notice.